Evaxion to Develop Tailored Novel Cancer Vaccines Based upon a New Untapped Source of AI-Discovered TargetsGlobeNewsWire • 01/24/24
Evaxion to Unveil Potentially Groundbreaking AI-Immunology™ Precision Cancer Vaccine ConceptGlobeNewsWire • 11/28/23
Evaxion Presents Proof-of-Principle for Its Unique AI Model Predicting Responses to Cancer ImmunotherapyGlobeNewsWire • 11/15/23
Evaxion Shares Latest EVX-01 Phase 2 Clinical Data in Webinar with Key Opinion Leader Adnan KhattakGlobeNewsWire • 11/06/23
Evaxion Announces Encouraging Initial Phase 2 Clinical Data on Its Personalized Cancer Vaccine EVX-01GlobeNewsWire • 10/31/23
New and Exciting Clinical Data on Evaxion's AI-Immunology™-Based Personalized Cancer Vaccines to be PresentedGlobeNewsWire • 10/26/23
Evaxion Partners With Pharmaceutical Company Afrigen Biologics to Develop Novel mRNA Vaccine Against GonorrheaGlobeNewsWire • 09/20/23
Evaxion expands preclinical bacterial vaccine pipeline in collaboration with leading pharmaceutical companyGlobeNewsWire • 09/18/23
Revolutionizing Vaccine Discovery: New Data Validates Evaxion AI Platform, Offering Promise to Reduce Risk and Cost in Infectious Disease Vaccine DevelopmentGlobeNewsWire • 09/11/23
Evaxion announces financing commitments totaling up to USD 20 million with Negma GroupGlobeNewsWire • 08/01/23
Evaxion presents promising results on EVX-B1, an AI-designed vaccine against Staphylococcus aureusGlobeNewsWire • 07/31/23